Stryker (NYSE: SYK) reported Q4 EPS of $3.46, $0.19 better than the analyst estimate of $3.27. Revenue for the quarter came in at $5.8 billion versus the consensus estimate of $5.6 billion.

GUIDANCE:

Stryker sees FY2024 EPS of $11.70-$12.00, versus the consensus of $11.56.

• Based on our momentum from 2023, strong procedural volumes, healthy demand for capital products and a stabilizing macro-economic environment, we expect 2024 organic net sales growth(2) to be in the range of 7.5% to 9.0% and expect adjusted net earnings per diluted share(2) to be in the range of $11.70 to $12.00. Based on the steady progress of our pricing actions, we would expect the full year impact of price to be roughly flat. If foreign exchange rates hold near current levels, we anticipate sales will be modestly unfavorably impacted for the full year, being more negative in the first half of the year. We expect adjusted net earnings per diluted share(2) will be negatively impacted by foreign exchange rates approximately $0.05 to $0.10. This is included in our guidance.

For earnings history and earnings-related data on Stryker (SYK) click here.